CO2023015528A2 - Estimuladores de guanilil ciclasa soluble (sgc) - Google Patents
Estimuladores de guanilil ciclasa soluble (sgc)Info
- Publication number
- CO2023015528A2 CO2023015528A2 CONC2023/0015528A CO2023015528A CO2023015528A2 CO 2023015528 A2 CO2023015528 A2 CO 2023015528A2 CO 2023015528 A CO2023015528 A CO 2023015528A CO 2023015528 A2 CO2023015528 A2 CO 2023015528A2
- Authority
- CO
- Colombia
- Prior art keywords
- sgc
- stimulators
- guanylyl cyclase
- increase
- soluble guanylyl
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title abstract 3
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 6
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Estimuladores de la guanilil ciclasa soluble (sGC), sales farmacéuticamente aceptables de los mismos y formulaciones farmacéuticas que los comprenden y sus usos, solos o en combinación con uno o más agentes adicionales, para el tratamiento de diversas enfermedades, en las cuales es deseable un aumento en la concentración del óxido nítrico (NO) y/o un aumento en la concentración del monofosfato de guanosina cíclico (cGMP), o ambas cosas, o un aumento de la expresión de la ruta del NO. En algunas formas de realización, los compuestos son los de la Tabla I o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177020P | 2021-04-20 | 2021-04-20 | |
| US202163229248P | 2021-08-04 | 2021-08-04 | |
| PCT/US2022/025310 WO2022225903A1 (en) | 2021-04-20 | 2022-04-19 | Sgc stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023015528A2 true CO2023015528A2 (es) | 2024-02-26 |
Family
ID=81579984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0015528A CO2023015528A2 (es) | 2021-04-20 | 2023-11-17 | Estimuladores de guanilil ciclasa soluble (sgc) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240208979A1 (es) |
| EP (1) | EP4326722A1 (es) |
| JP (1) | JP2024515119A (es) |
| KR (1) | KR20240058047A (es) |
| AU (1) | AU2022261862A1 (es) |
| BR (1) | BR112023021851A2 (es) |
| CA (1) | CA3216127A1 (es) |
| CL (1) | CL2023003105A1 (es) |
| CO (1) | CO2023015528A2 (es) |
| CR (1) | CR20230532A (es) |
| IL (1) | IL307865A (es) |
| TW (1) | TW202309038A (es) |
| WO (1) | WO2022225903A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086182A1 (en) * | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
| WO2024086179A1 (en) * | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2008296974B2 (en) | 2007-09-06 | 2013-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| BRPI1008793A2 (pt) | 2009-02-26 | 2016-03-08 | Merck Sharp & Dohme | composto, uso de um composto, e, composição farmacêutica |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US9365574B2 (en) | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| EP3310782B1 (en) * | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| JP7050759B2 (ja) | 2016-09-02 | 2022-04-08 | サイクレリオン・セラピューティクス，インコーポレーテッド | 縮合二環式ｓｇｃ刺激剤 |
| CA3086207A1 (en) | 2017-12-19 | 2019-06-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
-
2022
- 2022-04-19 CR CR20230532A patent/CR20230532A/es unknown
- 2022-04-19 BR BR112023021851A patent/BR112023021851A2/pt unknown
- 2022-04-19 AU AU2022261862A patent/AU2022261862A1/en active Pending
- 2022-04-19 WO PCT/US2022/025310 patent/WO2022225903A1/en active Application Filing
- 2022-04-19 JP JP2023565192A patent/JP2024515119A/ja active Pending
- 2022-04-19 US US18/287,612 patent/US20240208979A1/en active Pending
- 2022-04-19 TW TW111114883A patent/TW202309038A/zh unknown
- 2022-04-19 KR KR1020237039779A patent/KR20240058047A/ko unknown
- 2022-04-19 CA CA3216127A patent/CA3216127A1/en active Pending
- 2022-04-19 IL IL307865A patent/IL307865A/en unknown
- 2022-04-19 EP EP22721237.0A patent/EP4326722A1/en active Pending
-
2023
- 2023-10-18 CL CL2023003105A patent/CL2023003105A1/es unknown
- 2023-11-17 CO CONC2023/0015528A patent/CO2023015528A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240208979A1 (en) | 2024-06-27 |
| CL2023003105A1 (es) | 2024-03-22 |
| IL307865A (en) | 2023-12-01 |
| EP4326722A1 (en) | 2024-02-28 |
| CR20230532A (es) | 2024-03-22 |
| BR112023021851A2 (pt) | 2024-02-06 |
| TW202309038A (zh) | 2023-03-01 |
| KR20240058047A (ko) | 2024-05-03 |
| CA3216127A1 (en) | 2022-10-27 |
| AU2022261862A1 (en) | 2023-11-30 |
| WO2022225903A1 (en) | 2022-10-27 |
| JP2024515119A (ja) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015528A2 (es) | Estimuladores de guanilil ciclasa soluble (sgc) | |
| CO2019001760A2 (es) | Estimuladores de sgc | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
| CL2019001256A1 (es) | Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de sgc. | |
| CO2022017049A2 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| CL2021001536A1 (es) | 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden | |
| EA202091502A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2021011319A2 (es) | Tratamientos combinados para su uso en el tratamiento del cáncer | |
| AR125378A1 (es) | Estimuladores de guanilil ciclasa soluble (sgc) | |
| AR125221A2 (es) | Estimuladores de sgc | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| PE20230258A1 (es) | Formulaciones liquidas de analogos de glucagon |